IVERIC bio Inc (ISEE) Stock Price, Quote, News and Overview
NASDAQ:ISEE - Nasdaq - US46583P1021 - Common Stock - Currency: USD
ISEE Quote, Performance and Key Statistics
39.95
+0.15 (+0.38%)
The current stock price of ISEE is 39.95 USD. In the past month the price increased by 4.55%. In the past year, price increased by 241.45%.
ISEE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ISEE
Company Profile
IVERIC bio, Inc. operates as a biopharmaceutical company. The company is headquartered in Parsippany, New Jersey and currently employs 74 full-time employees. The company went IPO on 2013-09-25. The firm is focused on the discovery and development of treatments for retinal diseases with unmet medical needs. Its lead asset is its clinical-stage product candidate, avacincaptad pegol, which is also referred to as ACP or Zimura, a complement C5 inhibitor. Zimura is targeting diseases including geographic atrophy (GA), intermediate age-related macular degeneration (AMD), and autosomal recessive Stargardt disease (STGD1). In addition to ACP, the Company is also developing its preclinical product candidate, IC-500, a high temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA secondary to AMD and potentially other age-related retinal diseases. Its portfolio also includes several ongoing gene therapy research programs, each of which uses adeno-associated virus (AAV) for gene delivery. These AAV mediated gene therapy programs are targeting the orphan inherited retinal diseases (IRDs).
Company Info
IVERIC bio Inc
8 Sylvan Way, Suite 2372
Parsippany NEW JERSEY 10001 US
CEO: Glenn P. Sblendorio
Employees: 74
Company Website: https://ivericbio.com/
Phone: 16094746755.0
IVERIC bio Inc / ISEE FAQ
What is the stock price of IVERIC bio Inc today?
The current stock price of ISEE is 39.95 USD. The price increased by 0.38% in the last trading session.
What is the ticker symbol for IVERIC bio Inc stock?
The exchange symbol of IVERIC bio Inc is ISEE and it is listed on the Nasdaq exchange.
On which exchange is ISEE stock listed?
ISEE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for IVERIC bio Inc stock?
14 analysts have analysed ISEE and the average price target is 39.88 USD. This implies a price decrease of -0.17% is expected in the next year compared to the current price of 39.95. Check the IVERIC bio Inc stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is IVERIC bio Inc worth?
IVERIC bio Inc (ISEE) has a market capitalization of 5.51B USD. This makes ISEE a Mid Cap stock.
How many employees does IVERIC bio Inc have?
IVERIC bio Inc (ISEE) currently has 74 employees.
What are the support and resistance levels for IVERIC bio Inc (ISEE) stock?
IVERIC bio Inc (ISEE) has a support level at 39.48 and a resistance level at 39.96. Check the full technical report for a detailed analysis of ISEE support and resistance levels.
Should I buy IVERIC bio Inc (ISEE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ISEE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ISEE, evaluating the profitability, health, valuation and growth aspects
- IVERIC bio Inc (ISEE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IVERIC bio Inc (ISEE) Sales and EPS estimates to see what analysts future expectations are.
- IVERIC bio Inc (ISEE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IVERIC bio Inc (ISEE) Insider and Institutional Ownership to learn about the owners and their transactions.
- IVERIC bio Inc (ISEE) Stock Chart to make your own analysis
- IVERIC bio Inc (ISEE) Latest news and press-releases to stay up to date.
Does IVERIC bio Inc (ISEE) stock pay dividends?
ISEE does not pay a dividend.
When does IVERIC bio Inc (ISEE) report earnings?
IVERIC bio Inc (ISEE) will report earnings on 2023-07-24, before the market open.
What is the Price/Earnings (PE) ratio of IVERIC bio Inc (ISEE)?
IVERIC bio Inc (ISEE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.76).
ISEE Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ISEE. When comparing the yearly performance of all stocks, ISEE is one of the better performing stocks in the market, outperforming 99.25% of all stocks.
ISEE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ISEE. The financial health of ISEE is average, but there are quite some concerns on its profitability.
ISEE Financial Highlights
Over the last trailing twelve months ISEE reported a non-GAAP Earnings per Share(EPS) of -1.76. The EPS decreased by -55.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.2 |
ISEE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 53% to ISEE. The Buy consensus is the average rating of analysts ratings from 14 analysts.